Innovative Pulmonary Solutions (IPS) System for Targeted Lung Denervation

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2015

Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
DEVICE

TLD Therapy (IPS SystemTM)

Targeted Lung Denervation Therapy will be achieved bronchoscopically. As this is a single-arm, non-randomized study, it is anticipated that all patients who provide written informed consent and meet the protocol entry criteria will undergo treatment.

Trial Locations (3)

7505

Stellenbosch University, Capetown

9700

University Medical Center Groningen (UMCG), Groningen

Unknown

Panorama Medi-Clinic, Panorama

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Nuvaira, Inc.

INDUSTRY

NCT01483534 - Innovative Pulmonary Solutions (IPS) System for Targeted Lung Denervation | Biotech Hunter | Biotech Hunter